Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is not known to directly cause sunburn, and photosensitivity is not listed as a recognised side effect in the medicine's UK Summary of Product Characteristics. That said, people on Wegovy may find their skin reacts differently to sun exposure for indirect reasons tied to weight loss and appetite changes — and understanding why matters for anyone spending time outdoors this summer. As a prescription-only medicine, Wegovy is prescribed following a full clinical assessment; your prescriber is the right person to discuss any skin changes you notice during treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Searching for a direct link between Wegovy and sunburn turns up forum posts and social-media threads, but not clinical trial data. The UK-approved Summary of Product Characteristics for semaglutide does not list photosensitivity among its side effects, and the NHS medicines page for semaglutide makes no mention of increased sunburn risk as a known reaction.
The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks and recorded extensive safety data; heightened UV sensitivity was not a flagged finding. That does not mean individual experiences don't vary, only that the mechanism, if real, is not straightforwardly pharmacological. Individual differences in skin type, sun exposure habits and concurrent lifestyle changes all play a role.
The more credible explanation sits in what GLP-1 medicines do to appetite and fluid intake. Nausea, one of the most commonly reported side effects particularly after a dose step-up, can suppress the urge to eat and drink. Mild, persistent under-hydration is enough to compromise the skin's barrier function. Paired with more time outdoors as mobility improves and energy increases, the result can feel like greater sun sensitivity even when the medicine itself is not the direct cause.
Several real-world variables converge during Wegovy treatment that are worth taking seriously.
First, hydration. The GI side-effect profile of semaglutide, a GLP-1 receptor agonist used for weight management, includes nausea, loose stools and reduced appetite, making it easier to fall behind on fluids without noticing. Skin that is even mildly dehydrated burns faster and recovers more slowly. Keeping water intake consistent, especially through the first few weeks at a new dose, is a straightforward protective measure.
Second, nutritional changes. When appetite drops sharply, the quality as well as the quantity of intake tends to fall. Fat-soluble nutrients including vitamins D and E play a role in skin resilience and UV recovery. A reduced-calorie diet that skews towards protein and processed convenience food can leave gaps. This is one reason prescribers often discuss dietary quality alongside treatment, not just calorie targets.
Third, body composition change. As fat mass decreases, the skin's underlying structure changes too, and some people notice their skin feels thinner or more reactive. This is a normal feature of significant weight loss, not a sign that something has gone wrong.
If you are curious about how semaglutide burns fat and what the evidence behind that process shows, that question is covered in detail, and there is also a dedicated page on whether semaglutide burns fat or muscle and how that balance plays out as well as a page on whether semaglutide specifically helps reduce belly fat for those interested in where changes tend to occur first.
Nothing about semaglutide requires a radical change to how you approach sun safety. The basics become more important, not different.
SPF 30 or higher applied generously and reapplied every two hours is standard NHS guidance for everyone in the UK from April to September, and is not specific to people on weight-loss treatment. On Wegovy, the case for being consistent rather than casual about it is simply stronger. Protective clothing and shade during peak UV hours (roughly 11am to 3pm) add a reliable layer that does not depend on remembering to reapply cream.
Staying well hydrated is the intervention most directly relevant to the indirect sensitivity described above. A useful prompt: if nausea is reducing your appetite for drinks as well as food, treating water intake as a deliberate task rather than an instinctive one helps. The same principle applies to maintaining protein and vegetable intake even when appetite is low.
If you notice an injection-site reaction coinciding with sun exposure (localised redness, warmth or swelling at the site where the pen was used) tell your prescriber. Injection sites on the abdomen, thigh or upper arm can occasionally be more reactive to heat and UV in the days after use. The pen itself arrives ready to use; if you are waiting for your plain, untracked DPD box and wondering whether sun storage matters, the answer is yes: keep the pen refrigerated until use, and refer to the patient information leaflet for the exact out-of-fridge window.
Most sunburn on treatment will behave exactly like sunburn off it. Cool the skin, moisturise, stay out of the sun, drink plenty of water. That is straightforward.
A reaction that behaves unusually warrants a closer look. Blistering that is disproportionate to apparent sun exposure, a widespread rash across areas that were not exposed, or hives appearing after sun contact are worth raising with a GP or pharmacist promptly. These could indicate a separate photosensitivity condition, a reaction to another medicine taken alongside Wegovy, or in rare cases an allergic reaction unrelated to UV altogether.
Any suspected side effect can and should be reported to the MHRA through the Yellow Card scheme, which is open to patients as well as clinicians. Wegovy remains under additional MHRA monitoring (Black Triangle), so reports from people using it genuinely contribute to the ongoing safety picture. Your prescriber or our team via our contact page can also advise if something does not feel right between scheduled reviews.
For anyone considering starting Wegovy for weight management, a full clinical assessment is the first step. If you are wondering whether Wegovy helps burn fat and what the evidence suggests, that question is covered in detail before your consultation. The prescribers at our clinical team review every consultation personally, and questions about skin, existing conditions or anything else that feels relevant are part of that conversation, not an afterthought. You can also browse our frequently asked questions for more on what the assessment covers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.